CEO Michael Gilman said Arrakis faced an “unbelievable amount of skepticism” when it got started around 2017. In an interview with the Business Journal, Gilman explains how the company charted ...
Arrakis Therapeutics Inc. has presented data on its RNA-targeted small-molecule (rSM) drug program for the treatment of myotonic dystrophy type 1 (DM1). The company’s proprietary RNA‐specific chemical ...
“Dune: Prophecy” finally took some characters to the fabled planet Arrakis in the finale of Season 1, but much more of the locale is to come in the second season. The first season of the sci ...